Biocryst Pharmaceuticals agreed to acquire Astria Therapeutics for about $700 million in cash and stock, adding Astria’s long‑acting injectable navenibart to Biocryst’s hereditary angioedema (HAE) portfolio. The deal pairs Biocryst’s marketed oral HAE therapy with a late‑stage, infrequent‑dosing antibody intended to prevent swelling attacks and compete with existing long‑acting injectables. Company statements and analyst notes framed the acquisition as a strategic move to secure a multi‑product HAE franchise and diversify delivery options. BioCryst projects the combined portfolio will broaden patient choice and improve competitive positioning in a crowded HAE market; the transaction is expected to close next year pending customary approvals.